Alkermes plc (ALKS)
$
29.62
-0.04 (-0.14%)
Key metrics
Financial statements
Free cash flow per share
2.9734
Market cap
4.9 Billion
Price to sales ratio
3.2148
Debt to equity
0.0413
Current ratio
3.6716
Income quality
1.5969
Average inventory
191.5 Million
ROE
0.2140
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Alkermes plc, a biopharmaceutical company founded in 1987 and headquartered in Dublin, Ireland, focuses on researching, developing, and commercializing pharmaceutical products to meet the unmet medical needs of patients in various therapeutic areas. The company has a strong market presence, reporting substantial revenue of $1,557,632,000.00 which underscores its operational success. The EBITDA ratio stands at 0.32 highlighting the company's operational efficiency. Furthermore, the earnings per share (EPS) is reported at $2.22 indicating profitability on a per-share basis. Alkermes also earned an interest income of $42,450,000.00 showcasing its ability to generate returns from financial investments. Additionally, the net total of other income and expenses is reported at $23,114,000.00 reflecting the impact of non-core financial activities on the overall financial standing of the company. Among its marketed products are ARISTADA, VIVITROL, and VUMERITY, which address critical psychiatric and neurological conditions, emphasizing the company’s commitment to addressing diverse health challenges. Positioned as a key player in the Biotechnology industry, Alkermes contributes significantly to the overall market landscape while belonging to the Healthcare sector, driving innovation and growth. The stock is affordable at $27.79 making it suitable for budget-conscious investors. With a mid-range market capitalization of $4,890,780,617.00 the company is considered a steady performer in the market. Furthermore, the stock has a high average trading volume of 2,322,709.00 indicating strong liquidity and investor interest. Alkermes demonstrates a robust portfolio that includes not only marketed products but also promising drug candidates in development, such as LYBALVI and nemvaleukin alfa, which aim to further expand the treatment options available to patients.
Is Alkermes plc (ALKS) a good investment?
Investing in Alkermes plc (ALKS) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A+, with a Bullish outlook. Always conduct your own research before investing.
What is Alkermes plc (ALKS)'s stock forecast?
Analysts predict Alkermes plc stock to fluctuate between $25.17 (low) and $36.45 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Alkermes plc's market capitalization?
As of 2026-01-12, Alkermes plc's market cap is $4,890,780,617, based on 165,117,509 outstanding shares.
How does Alkermes plc compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Alkermes plc has a Lower Market-Cap, indicating a difference in performance.
How can I buy Alkermes plc (ALKS) stock?
To buy Alkermes plc (ALKS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALKS. Place an order (Market, Limit, etc.).
What is the best time to invest in Alkermes plc?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Alkermes plc stock ever split?
Alkermes plc's last stock split was 2:1 on 2000-05-15.
How did Alkermes plc perform in the last earnings report?
Revenue: $1,557,632,000 | EPS: $2.22 | Growth: 3.74%.
Where can I find Alkermes plc's investor relations reports?
Visit https://www.alkermes.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Alkermes plc?
You can explore historical data from here
What is the all-time high and low for Alkermes plc stock?
All-time high: $36.45 (2025-02-18) | All-time low: $21.24 (2021-12-01).
What are the key trends affecting Alkermes plc stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
defenseworld.net
Alkermes plc (NASDAQ: ALKS - Get Free Report) EVP Craig Hopkinson sold 5,000 shares of the stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $30.00, for a total value of $150,000.00. Following the completion of the transaction, the executive vice president owned 61,740 shares of
seekingalpha.com
Alkermes is transforming into a fully integrated biopharma, leveraging Vibrance-2 results and the Avadel acquisition for competitive advantage in sleep medicine. ALKS's robust legacy portfolio funds rapid R&D expansion, with Lybalvi sales up 32% and strong gross-to-net dynamics supporting operational profitability. Alixorexton's Phase 2 success in both narcolepsy types and idiopathic hypersomnia, plus a clean safety profile, significantly de-risk the clinical pipeline.
zacks.com
Alkermes wins FDA Breakthrough Therapy status for alixorexton in NT1 after Vibrance-1 data shows improvement in wakefulness.
businesswire.com
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 44th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, Jan. 13, 2026 at 10:30 a.m. PST (1:30 p.m. EST/6:30 p.m. GMT). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc (Nasdaq: ALKS), a mid-cap growth.
zacks.com
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
seekingalpha.com
Alkermes plc (ALKS) Presents at Evercore 8th Annual Healthcare Conference Transcript
zacks.com
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?
reuters.com
Alkermes said on Wednesday it has sweetened its offer to buy Avadel Pharmaceuticals , beating a rival bid from Denmark's Lundbeck and valuing the sleep disorder drugmaker at up to $2.37 billion.
seekingalpha.com
Alkermes plc ( ALKS ) Shareholder/Analyst Call November 12, 2025 8:30 AM EST Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations Richard F. Pops - Chairman & CEO Craig Hopkinson - Executive VP of Research & Development and Chief Medical Officer Conference Call Participants Joon Lee - Truist Securities, Inc., Research Division Julian Pino - Stifel, Nicolaus & Company, Incorporated, Research Division Luke Herrmann - Robert W.
defenseworld.net
Alkermes plc (NASDAQ: ALKS - Get Free Report) fell 6.2% on Friday after Wells Fargo and Company lowered their price target on the stock from $42.00 to $37.00. Wells Fargo and Company currently has an overweight rating on the stock. Alkermes traded as low as $28.67 and last traded at $29.0780. 2,270,621 shares changed hands during
See all news
